L. Dieleman

Review and clinical perspectives for the use of infliximab in ulcerative colitis.

A. Griffiths, A. Bitton, G. Greenberg, 2008, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease

L. Dieleman, R. Fedorak, K. Kroeker, 2014, Alimentary pharmacology & therapeutics.

Increased Intestinal Permeability is Associated with Later Development of Crohn's Disease.

A. Paterson, M. Surette, C. Lees, 2020, Gastroenterology.

Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohn's Disease.

M. Surette, P. Moayyedi, G. Kaplan, 2019, Inflammatory bowel diseases.

Association of host genome with intestinal microbial composition in a large healthy cohort

A. Paterson, P. Moayyedi, G. Kaplan, 2016, Nature Genetics.

Clinical, endoscopic and radiographic outcomes with ustekinumab in medically‐refractory Crohn's disease: real world experience from a multicentre cohort

G. Kaplan, S. Devlin, R. Panaccione, 2017, Alimentary pharmacology & therapeutics.

Maintenance of clinical benefit in Crohn’s disease patients after discontinuation of infliximab: long‐term follow‐up of a single centre cohort

Clarence K. Wong, L. Gramlich, L. Dieleman, 2010, Alimentary pharmacology & therapeutics.

Novel fecal biomarkers that precede clinical diagnosis of ulcerative colitis.

P. Moayyedi, G. Kaplan, M. Silverberg, 2020, Gastroenterology.

Prevalence of Epstein–Barr Virus in a population of patients with inflammatory bowel disease: a prospective cohort study

R. Fedorak, K. Kroeker, L. Dieleman, 2013, Alimentary pharmacology & therapeutics.

An imbalance in mucosal cytokine profile causes transient intestinal inflammation following an animal's first exposure to faecal bacteria and antigens

R. Fedorak, Beate C. Sydora, M. Lupicki, 2010, Clinical and experimental immunology.